NeuroRx Initiates Pivotal Study for NRX-101, a Breakthrough Designation Therapy Targeting Suicidal Bipolar Depression - PRNewswire

Submitted by Anonymous (not verified) on Tue, 07/09/2019 - 13:46

NeuroRx Initiates Pivotal Study for NRX-101, a Breakthrough Designation Therapy Targeting Suicidal Bipolar Depression  PRNewswirePHILADELPHIA, July 9, 2019 /PRNewswire/ -- NeuroRx, Inc., a clinical stage biopharma company focused on development of drugs targeting depression and ...